Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis patient to become less susceptible or resistant to treatment with interferon ?, said method comprising determining in a sample obtained from said patient the presence of one or more SNP(s) selected from the group consisting of SNPs defined by the sequences of SEQ ID NOs 12, 17, 2, 3, 5, 7, 8, 1, 4, 6, 9, 10, 11, 13, 14, 15 and 16, wherein the presence of one or more of said SNP(s) in said sample is indicative for said predisposition.

Abstract: This invention relates to a method of diagnosing a predisposition for or the occurrence of treatment emergent suicidal ideation in an individual, the method comprising determining the presence or absence of one, more or all SNPs selected from the SNPs defined by SEQ ID NOs: 8, 18, 19, 47, 50, 52, 56, 64, 73, 86, 87, 92, 94, 95, 97 and 99.

Abstract: The present invention relates to a method of identifying a predisposition for developing posttraumatic stress disorder (PTSD) in a subject comprising assessing in a sample obtained from said subject the expression level of one or more genes selected from the FK506 binding protein 5 (FKBP5) gene, the signal transducer and activator of transcription (STAT5B) gene and the nuclear factor I/A (NFIA) gene, wherein a decrease in the expression level of said one or more genes as compared to the expression level of the corresponding gene(s) of a control is indicative of a predisposition for developing PTSD. Further, the invention relates to a method of identifying a compound capable of preventing or treating PTSD or capable of serving as a lead compound for developing a compound capable of preventing or treating PTSD and also to a method of selecting a therapy to prevent or treat PTSD.

Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-? (IFN-?) and/or interferon-? (IFN-?) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means.

Abstract: The present invention relates to methods, compositions and kits for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The present invention relates to methods, compositions, kits and reagents for the diagnosis and treatment of anxiety disorders.

Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-? (IFN-?) and/or interferon-? (IFN-?) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means.

Abstract: The present invention relates to methods, compositions and kits for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the invention provides a method of predicting the response to antidepressant therapy. Furthermore, a method of developing an anti-depressant drug, and pharmaceutical compositions are provided.

Abstract: The present invention relates to new methods of identifying compounds that inhibit or reduce bag-1 mediated down-regulation of gluocorticoid-receptor (GR) tansactivation. These methods rely on the surprising findings, that first, a (poly)peptide comprising the motif X-Lys-Lys-Lys-Y-Arg-Arg-Arg also present is the cochaperone bag-1 is sufficient for DNA binding of this cochaperone and, second, this motif but not the E2X4 domain of bag-1 is required for inhibition or reduction of FR transactivation. The present invention also relates to methods of refining the compounds identified with the above method as well as to methods of producing pharmaceutical compositions wherein compounds identified or compounds refined by the above-recited methods of the invention are formulated with a pharmaceutically acceptable carrier or diluent.